Skip to main content
Log in

MYELODYSPLASTIC NEOPLASM

Myelodysplastic neoplasm with isolated thrombocytopenia and immune thrombocytopenic purpura in adults: insights from a comparison of two national registries

  • Letter
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1: Kaplan–Meier curve of overall survival and leukemia-free survival of patients with MDS-IT, as compared with patients in the general MDS cohort.
Fig. 2: Differentiating between MDS-IT and ITP.

Data availability

The original data of this study can be obtained via e-mail to Prof. I. Kotsianidis (ikotsian@med.duth.gr).

References

  1. Adès L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet. 2014;383:2239–52.

    Article  PubMed  Google Scholar 

  2. Najean Y, Lecompte T. Chronic pure thrombocytopenia in elderly patients. An aspect of the myelodysplastic syndrome. Cancer. 1989;64:2506–10.

    Article  CAS  PubMed  Google Scholar 

  3. Qian J, Xue Y, Pan J, Cen J, Wang W, Chen Z. Refractory thrombocytopenia, an unusual myelodysplastic syndrome with an initial presentation mimicking idiopathic thrombocytopenic purpura. Int J Hematol. 2005;81:142–7.

    Article  CAS  PubMed  Google Scholar 

  4. Kuroda J, Kimura S, Kobayashi Y, Wada K, Uoshima N, Yoshikawa T. Unusual myelodysplastic syndrome with the initial presentation mimicking idiopathic thrombocytopenic purpura. Acta Haematol. 2002;108:139–43.

    Article  CAS  PubMed  Google Scholar 

  5. Menke DM, Colon-Otero G, Cockerill KJ, Jenkins RB, Noel P, Pierre RV. Refractory thrombocytopenia. A myelodysplastic syndrome that may mimic immune thrombocytopenic purpura. Am J Clin Pathol. 1992;98:502–10.

    Article  CAS  PubMed  Google Scholar 

  6. Sashida G, Takaku TI, Shoji N, Nishimaki J, Ito Y, Miyazawa K, et al. Clinico-hematologic features of myelodysplastic syndrome presenting as isolated thrombocytopenia: an entity with a relatively favorable prognosis. Leuk Lymphoma. 2003;44:653–8.

    Article  PubMed  Google Scholar 

  7. Breccia M, Latagliata R, Cannella L, Carmosino I, Santopietro M, Loglisci G, et al. Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients. Leuk Lymphoma. 2010;51:783–8.

    Article  PubMed  Google Scholar 

  8. Waisbren J, Dinner S, Altman J, Frankfurt O, Helenowski I, Gao J, et al. Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia. Int J Hematol. 2017;105:44–51.

    Article  CAS  PubMed  Google Scholar 

  9. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703–19.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data. Blood. 2022;140:1200–28.

    Article  Google Scholar 

  11. Arnold DM. Bleeding complications in immune thrombocytopenia. Hematol Am Soc Hematol Educ Program. 2015;2015:237–42.

    Article  Google Scholar 

  12. Gyan E, Andrieu V, Sanna A, Caille A, Schemenau J, Sudaka I, et al. Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis. Br J Haematol. 2016;175:975–9.

    Article  PubMed  Google Scholar 

  13. Gupta R, Soupir CP, Johari V, Hasserjian RP. Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. Br J Haematol. 2007;139:265–8.

    Article  PubMed  Google Scholar 

  14. Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3:3829–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3:3780–817.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We would like to thank all local investigators for their contribution to data acquisition for the Hellenic National Registry of Myelodysplastic and Hypoplastic Syndromes and the ITP Registry of the Hellenic Society of Hematology. We declare no funding for this research from any funding agency in the public, commercial, or not-for-profit sectors. There was no external funding for this research from any funding agency in the public, commercial or not-for-profit sectors.

Author information

Authors and Affiliations

Authors

Contributions

Contribution: IK conceived the idea for this study and designed the study. KL and V. Papadopoulos contributed to the concept of the study. KL, V. Papadopoulos, GV, and IK collected, analyzed and interpreted data and reviewed the literature. KL and IK drafted the manuscript. ES, AK, CP, AGG, MP, SGP, PTD, V. Pappa, NAV, DT, TPV, EH, EB, MX, AM, PZ, PP, MD, SK, MP, SP, AV, FK, NH, IA, AS, and HP collected data. All authors reviewed and approved the final version of the manuscript.

Corresponding author

Correspondence to Konstantinos Liapis.

Ethics declarations

Competing interests

IK, NAV, AS, and V. Pappa have received research funding from Celgene Corporation for work outside this study. IK, SGP, TPV, AGG, EH, PP, AK, AS, V. Pappa and NAV have received honoraria from Genesis Pharma Hellas S.A. for work outside this study. All other authors: no conflicts of interest.

Ethical approval

This study was approved by the Ethics Committee of the Hellenic Society of Hematology (Protocol: No.8/26-3-2008). This study was done in accordance with the ethical standards of the Institutional Research Committees of the participating centers, and in compliance with the ethical principles of the Declaration of Helsinki.

Informed consent

The basis for this study formed the database of the Hellenic National Registry of Myelodysplastic and Hypoplastic Syndromes (N = 2972 patients) and the database of the ITP Registry of the Hellenic Society of Hematology (N = 1317 patients). All data were collected during routine patient care. This study was approved by the Ethics Committee of the Hellenic Society of Hematology (Protocol: No.8/26-3-2008).

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liapis, K., Papadopoulos, V., Pontikoglou, C. et al. Myelodysplastic neoplasm with isolated thrombocytopenia and immune thrombocytopenic purpura in adults: insights from a comparison of two national registries. Leukemia 37, 708–711 (2023). https://doi.org/10.1038/s41375-023-01819-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-023-01819-x

  • Springer Nature Limited

Navigation